Fenwick Represents A-Alpha Bio in $22.4 Million Series A2 Financing

Fenwick represented A-Alpha Bio, a synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, in its $22.4 million Series A2 financing. The round was led by previous investor Perceptive Xontogeny Ventures with participation from Madrona and other existing investors. Breakout Ventures joined the round as a new investor.

A-Alpha Bio intends to use the funds for further development of its AlphaSeq and AlphaBind platforms and accelerate their oncology-focused internal pipeline. More information can be obtained from the company’s announcement.

The transaction was led by corporate partner Bill Bromfield and associates Sam Millang and Warren Pugash.


Don’t have an account yet?